Printer Friendly

ADVANCED INTERVENTIONAL SYSTEMS ADDS NEW CATHETER TO CLINICAL TRIALS WITH EXCIMER LASER SYSTEM

 ADVANCED INTERVENTIONAL SYSTEMS ADDS NEW CATHETER
 TO CLINICAL TRIALS WITH EXCIMER LASER SYSTEM
 Directional Catheter Selectively Targets Plaque
 in Coronary Arteries
 IRVINE, Calif., Jan. 16 /PRNewswire/ -- The federal Food and Drug Administration (FDA) has approved a new directional catheter designed by Advanced Interventional Systems (NASDAQ: LAIS) for use as an investigational device in the company's clinical trials to treat coronary disease, the company announced today.
 According to Advanced Interventional Systems' chief executive officer, Robert E. Wall, the innovative and distinguishing feature of the company's new catheter is its ability to aim selectively in blocked arteries to remove a greater amount of plaque than was previously possible. The recent FDA action provides the company the opportunity to test the new catheter in a controlled clinical environment with leading interventional cardiologists throughout the country, he said.
 "This new directional excimer laser coronary angioplasty catheter is designed to allow the cardiologist to remove plaque in blocked coronary arteries which are difficult to treat with other technologies, including balloon angioplasty. Therefore, it has the potential to further expand the applications for the excimer laser procedure," Wall said.
 Existing catheters designed by the company, which do not include the directional feature, are currently utilized as investigational devices with an overall procedural success rate of 90 percent. Interventional cardiologists involved in the company's clinical trials continue to use these catheters to treat certain complex cases of heart disease difficult to treat with balloon angioplasty.
 Even though the results reported last week at a medical symposium presented by Washington Cardiology Center and Washington Hospital Center in Washington, D.C., are very preliminary, the new catheter appears to offer a unique alternative to further expand cardiologists' less-invasive alternatives for treating complex cases of heart disease.
 During the excimer laser procedure, laser energy is transmitted through a catheter and administered in pulses, until it literally breaks down plaque into gases and micro-miniature particulate that is eliminated through the body's natural waste system.
 Advanced Interventional Systems pioneered the procedure for treating heart disease with the excimer laser and was the first company to receive panel recommendation from the FDA for approval. The company is awaiting final approval from the FDA to sell its Dymer 200+ system commercially.
 -0- 1/16/92
 /CONTACT: Connie McCluskey of Advanced Interventional Systems, 714-586-1342/
 (LAIS) CO: Advanced Interventional Systems ST: California IN: MTC HEA SU: PDT


EH-JL -- LA008 -- 0331 01/16/92 08:07 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 16, 1992
Words:400
Previous Article:WEST ONE BANCORP RELEASES FOURTH-QUARTER EARNINGS
Next Article:IDEC PHARMACEUTICALS TO BEGIN HUMAN CLINICAL STUDY OF MONOCLONAL ANTIBODY-BASED THERAPEUTIC FOR TREATMENT OF HIV INFECTION
Topics:


Related Articles
ADVANCED INTERVENTIONAL SYSTEMS RECEIVES FDA PRE-MARKET APPROVAL
ADVANCED INTERVENTIONAL SYSTEMS REPORTS FISCAL 1991 RESULTS; FINANCIAL PERFORMANCE CONSISTENT WITH RECENT ANALYST PROJECTIONS
ADVANCED INTERVENTIONAL SYSTEMS ANNOUNCES SECOND QUARTER RESULTS
LAIS EXPANDS INTERNATIONAL MARKETING EFFORT
LAIS DOWNSIZES DUE TO SLOWER THAN EXPECTED GROWTH; NINE MONTH REVENUES INCREASE FROM SAME PERIOD IN 1991, BUT ARE BELOW EXPECTATIONS
LAIS COMPLETES CORPORATE RESTRUCTURING EFFORTS
ADVANCED INTERVENTIONAL SYSTEMS ANNOUNCES THIRD QUARTER RESULTS
CARDIOLOGISTS AT WASHINGTON HOSPITAL CENTER LEAD INVESTIGATION WITH INNOVATIVE LASER CATHETER
ADVANCED INTERVENTIONAL SYSTEMS REPORTS 1993 FIRST QUARTER RESULTS
ADVANCED INTERVENTIONAL SYSTEMS RECEIVES MARKETING APPROVAL FOR TWO OF ITS 50-MICRON FIBEROPTIC-BASED CATHETERS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters